<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201108097270N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2012-01-27</date_registration>
      <primary_sponsor>Skin research center, Shohada-e-Tajrish hospital</primary_sponsor>
      <public_title>New way to treating the smile lines</public_title>
      <acronym></acronym>
      <scientific_title>The evaluation of efficacy and adverse effects of subcision in the correction of nasolabial fold</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-02-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>10</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/7710</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>improvement of nasolabial fold by subcision.</hc_freetext>
      <i_freetext>At first, the desired area is marked and local anesthesia is undergone using lidocain 1%. The subcision needle penetrates the skin from the margin of the nasolabial fold while its sharp edge is upward. The needle will be rotated till its tip become parallel to the dermoepidermal junction. The necessary movement will be done for releasing the fibrotic band ..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link>http://www.hindawi.com/journals/drp/2015/976153/</results_url_link>
      <results_summary>The evaluation of efficacy and adverse effects of subcision in the correction of nasolabial fold &lt;br /&gt;&#13;
&lt;br /&gt;&#13;
Background. A prominent nasolabial fold (NLF) is a cosmetic problem. Currently, numerous therapeutic modalities are available&lt;br /&gt;&#13;
for pronounced NLFs with variable efficacy. Objective. To determine the efficacy and safety of subcision using a hypodermic needle&lt;br /&gt;&#13;
for the correction of the prominentNLFs and its effect on skin elasticity. Methods. Sixteen patients with prominentNLFs underwent&lt;br /&gt;&#13;
subcision. The investigators’ assessment of improvement and the patients’ satisfaction were both recorded 1 and 6 months after the&lt;br /&gt;&#13;
procedure. Also,we evaluate the skin elasticity of NLFs before and after the treatment using a sensitive biometrologic device with the&lt;br /&gt;&#13;
measurement of cutaneous resonance running time (CRRT). Results. Thirteen (81.25%) patients showed a moderate improvement&lt;br /&gt;&#13;
at 1stmonth and 13 (81.25%) patients had at least a mild improvement at 6th month. There was no persistent side effect lasting more&lt;br /&gt;&#13;
than a few days. Mean CRRT at 1 and 6 months after the treatment was significantly higher compared to the baseline. Conclusion.&lt;br /&gt;&#13;
Subcision may be considered effective for the correction of pronounced NLFs. However, further controlled studies with larger&lt;br /&gt;&#13;
sample size are necessary to assess the efficacy of this technique in particular with use ofmore objective assessment of skin biometric&lt;br /&gt;&#13;
characteristics. This trial is registered with IRCT201108097270N1 (registered on January 27, 2012).                     </results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Reza Mahmoud Robati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Skin Research Center, Shohada-e-Tajrish hospital, Shahid Beheshti University of Medical Sciences</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 2274 1507</telephone>
        <email>robati@razi.tums.ac.ir</email>
        <affiliation>Skin Research Center, Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Reza Mahmoud Robati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Skin Research Center, Shohada-e-Tajrish hospital, Shahid Beheshti University of Medical Sciences</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 2274 1507</telephone>
        <email>rezarobati@sbmu.ac.ir</email>
        <affiliation>Skin Research Center, Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: 1. age 30-60y; 2.deep nasolabial fold. Exclusion criteria:1.age under 30y; 2.lactation &amp; pregnancy; 3.history of coagulopathy or use of anticouagulant drug; 4.active infection in facial zone; 5.inability to stay in the study; 6.history of collagen or elastin disorder and connective tissue disease; 7.history of facial skin cancer; 8.history of topical medication administration during 1 month before study except sunscreen; 9.history of cosmetic procedure during last year (laser,..); 10. history of filler injection in nasolabial fold during last 5 years.</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z41.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Procedure for purposes other than remedying health state, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>At first, the desired area is marked and local anesthesia is undergone using lidocain 1%. The subcision needle penetrates the skin from the margin of the nasolabial fold while its sharp edge is upward. The needle will be rotated till its tip become parallel to the dermoepidermal junction. The necessary movement will be done for releasing the fibrotic band .</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Nasolabial fold. Timepoint: before treatment,1 w, 1 m and 6 m after treatment. Method of measurement: photograph,reviscometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Bleeding. Timepoint: immediately after treatment and the day after. Method of measurement: observation.</sec_outcome>
      <sec_outcome>Ecchymosis. Timepoint: 2 hours ,1 day and 1 week after treatment. Method of measurement: observation.</sec_outcome>
      <sec_outcome>Infection. Timepoint: 1 w after treatment. Method of measurement: physical exam.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Skin research center, Shohada-e-Tajrish hospital</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2011-10-16</approval_date>
        <contact_name>Skin research center ethics committe, Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Shohada-e-Tajrish hospital, Shahid Beheshti University of Medical Sciences Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
